| U.S. Brand Names |
| Naphcon-A® Ophthalmic [OTC] |
 |
| Generic Available |
|
No |
|
| Synonyms |
| Pheniramine and Naphazoline |
|
| Pharmacological Index |
|
Ophthalmic Agent, Vasoconstrictor |
|
| Use |
|
Topical ocular vasoconstrictor |
|
| Pregnancy Risk Factor |
|
C |
|
| Contraindications |
|
Hypersensitivity to naphazoline, pheniramine, or any component |
|
| Adverse Reactions |
|
1% to 10%: Systemic effects due to absorption: Cardiovascular: Hypertension, cardiac irregularities Endocrine & metabolic: Hyperglycemia |
|
| Drug Interactions |
|
MAO inhibitors (hypertensive crisis possible) |
|
| Usual Dosage |
|
1-2 drops every 3-4 hours |
|
| Mental Health: Effects on Mental Status |
|
May cause nervousness or dizziness |
|
| Mental Health: Effects on Psychiatric Treatment |
|
TCAs and MAOIs may potentiate the pressor response of decongestants; monitor for changes in response |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
Discontinue drug and consult physician if ocular pain or visual changes occur, ocular redness or irritation, or condition worsens or persists more than 72 hours |
|
| Nursing Implications |
|
Discontinue drug and consult physician if ocular pain or visual changes occur, ocular redness or irritation, or condition worsens or persists more than 72 hours |
|
| Dosage Forms |
|
Solution, ophthalmic: Naphazoline hydrochloride 0.025% and pheniramine 0.3% (15 mL) |
|
|
Copyright © 2007 Drugs Area |
